We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+8.32%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$395M
AUM Growth
-$62.2M
Cap. Flow
-$70.5M
Cap. Flow %
-17.83%
Top 10 Hldgs %
40.77%
Holding
93
New
11
Increased
18
Reduced
29
Closed
19

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$8.57M
2
IMUX icon
Immunic
IMUX
+$5.02M
3
AMGN icon
Amgen
AMGN
+$4.6M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$4.28M
5
FULC icon
Fulcrum Therapeutics
FULC
+$3.65M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$18M
2
CRL icon
Charles River Laboratories
CRL
+$11.3M
3
ITMR
Itamar Medical Ltd. American Depository Shares
ITMR
+$7.96M
4
XLRN
Acceleron Pharma
XLRN
+$7.54M
5
NVRO
NEVRO CORP.
NVRO
+$5.93M

Sector Composition

Rank Sector Weight
1 Healthcare 97.83%
2 Industrials 0.81%
3 Technology 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
1
DexCom
DXCM
$32B
$24.9M 6.29%
181,832
-20,000
-10% -$2.52M
ACRS icon
2
Aclaris Therapeutics
ACRS
$869M
$23.5M 5.95%
1,306,460
-195,000
-13% -$3.13M
AVTR icon
3
Avantor
AVTR
$9.19B
$18M 4.55%
440,000
+86,059
+24% +$3.36M
UTHR icon
4
United Therapeutics
UTHR
$23.1B
$17.4M 4.4%
94,324
– –
IQV icon
5
IQVIA
IQV
$39.3B
$16.7M 4.23%
69,869
+1,500
+2% +$379K
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$29.3B
$14.2M 3.58%
74,967
– –
DHR icon
7
Danaher
DHR
$144B
$13.8M 3.49%
51,125
-11,844
-19% -$3.22M
SGEN
8
DELISTED
Seagen Inc. Common Stock
SGEN
$12.3M 3.12%
72,676
+27,500
+61% +$4.28M
CRL icon
9
Charles River Laboratories
CRL
$12.8B
$10.3M 2.61%
25,000
-27,245
-52% -$11.3M
NTRA icon
10
Natera
NTRA
$46.4B
$10M 2.54%
90,047
-30,500
-25% -$3.5M
COO icon
11
Cooper Companies
COO
$14.5B
$9.96M 2.52%
96,352
+22,000
+30% +$2.35M
GOSS icon
12
Gossamer Bio
GOSS
$87M
$9.89M 2.5%
786,870
– –
PODD icon
13
Insulet
PODD
$9.79B
$9.76M 2.47%
34,340
-1,000
-3% -$285K
CDMO
14
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$9.71M 2.46%
450,000
-25,000
-5% -$603K
FULC icon
15
Fulcrum Therapeutics
FULC
$297M
$9.56M 2.42%
338,796
+192,407
+131% +$3.65M
HZNP
16
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$8.74M 2.21%
79,767
+7,500
+10% +$779K
RCUS icon
17
Arcus Biosciences
RCUS
$3.64B
$8.25M 2.09%
236,637
-10,000
-4% -$311K
IMUX icon
18
Immunic
IMUX
$195M
$8.18M 2.07%
92,409
+51,000
+123% +$5.02M
ABBV icon
19
AbbVie
ABBV
$435B
$8.09M 2.05%
+75,000
New +$8.57M
APEN
20
DELISTED
Apollo Endosurgery, Inc.
APEN
$7.53M 1.91%
831,214
+140,000
+20% +$1.2M
HUM icon
21
Humana
HUM
$46.2B
$7.39M 1.87%
19,000
-13,681
-42% -$5.81M
CDXS icon
22
Codexis
CDXS
$158M
$6.65M 1.68%
286,067
+80,000
+39% +$1.89M
RGEN icon
23
Repligen
RGEN
$9.25B
$5.78M 1.46%
20,000
-18,740
-48% -$4.81M
CTLT
24
DELISTED
CATALENT, INC.
CTLT
$5.29M 1.34%
39,739
-15,000
-27% -$1.87M
IDXX icon
25
Idexx Laboratories
IDXX
$46.2B
$4.77M 1.21%
7,667
– –
1
2 3 4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2021 Portfolio in Review

As of Q3 2021, Parkman Healthcare Partners held 93 positions worth $395M, down 14% from $457M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Parkman Healthcare Partners withdrew a net $70.5M in Q3 2021, closing 19 positions and reducing 29 holdings. Its most notable exit was Intuitive Surgical, an estimated $18M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

Against the trend, Parkman Healthcare Partners opened a new position in AbbVie worth $8.09M.

  • Parkman Healthcare Partners's largest Q3 2021 buy was AbbVie: 75,000 shares worth $8.09M.
  • Parkman Healthcare Partners added most to Immunic in Q3 2021, an estimated $5.02M increase.
  • Parkman Healthcare Partners's biggest Q3 2021 reduction was Charles River Laboratories, cutting an estimated $11.3M.
  • Parkman Healthcare Partners fully exited Intuitive Surgical in Q3 2021, selling an estimated $18M.
  • Parkman Healthcare Partners's ten largest holdings make up 41% of its $395M portfolio in Q3 2021.
  • Parkman Healthcare Partners opened 11 new positions and closed 19 in Q3 2021.
  • Parkman Healthcare Partners's portfolio value fell 14% quarter-over-quarter to $395M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2021, filed 12 Nov 2021.